Navidea biopharmaceuticals reports third quarter 2021 financial results

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the third quarter and year-to-date for the period ended september 30, 2021. alexander l. cappello, chair of navidea's board of directors, said, “during this time of transition in our leadership, we remain focused on our mission of developing p
NAVB Ratings Summary
NAVB Quant Ranking